产后葡萄糖不耐受性测试策略的成本效益
Tatiana Acosta1, Evan Myers1, Kara McElligott1
1Department of Obstetrics and Gynecology, Duke University Medical Center.
North Carolina medical journal
|January 7, 2026
概括
产后查葡萄糖不耐受是非常重要的. 家庭禁食毛细血管葡萄糖 (FCG) 测试是有效的替代品,以2小时口服葡萄糖耐受性测试 (OGTT),当坚持是低.
科学领域:
- 生殖内分泌学 生殖内分泌学
- 代谢障碍 代谢障碍 代谢障碍
- 卫生经济学 卫生经济学
背景情况:
- 孕期糖尿病 (GDM) 可以导致持续的产后葡萄糖代谢异常.
- 有效的产后查策略对于早期发现和管理葡萄糖不耐症至关重要.
- 本研究评估了不同产后查方法的成本效益.
研究的目的:
- 为了比较四种不同的分娩后葡萄糖不耐受性查策略的成本和有效性.
- 确定影响这些策略成本效益的变量.
- 为指导产后葡萄糖不耐受性查协议提供一个模型.
主要方法:
- 用一个决策模型来比较四种查策略:仅限于住院的快速毛细血管葡萄糖 (FCG),住院的FCG与2小时口服葡萄糖耐受性测试 (OGTT),住院的FCG与家庭FCG测试,没有查.
- 关于临床概率和成本的数据来源于机构记录,文献和定价数据.
- 主要结局包括每位患者的成本,检测糖尿病和糖尿病前期的有效性,以及增量成本效益比率 (ICER).
主要成果:
- 战略成本在1167美元至1330美元之间,有效率在0%至25%之间.
- 与2小时的OGTT (策略2) 相比,家庭FCG测试 (策略3) 是最有效和最昂贵的,ICER为837美元.
- 策略2比单独的住院FCG (策略1) 更有效和昂贵,ICER为571.1美元.
结论:
- 家庭FCG测试为2小时OGTT提供了可行的替代方案,特别是当患者对OGTT的遵守率较低时.
- 开发的模型可以帮助优化产后葡萄糖不耐受性查协议.
- 早期诊断和干预通过有效的查来促进,尽量减少错过的机会.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K
Pathophysiology of Diabetes
3.1K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
3.1K
Hypoglycemia and Glucagon
822
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
822
Oral Hypoglycemic Agents: Biguanides and Glitazones
581
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
581
Diabetes: Management and Pharmacotherapy
858
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
858
Dipeptidyl Peptidase 4 Inhibitors
575
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
575


